TNFRSF10B: The Apoptotic Regulatory Hub of the Death Receptor Family

 Molecular Structure and Expression Regulation Characteristics

TNFRSF10B (also known as DR5 or TRAIL-R2) is a critical member of the tumor necrosis factor receptor superfamily, functioning as a type I transmembrane protein extensively involved in the regulation of programmed cell death. Comprising 468 amino acids, this receptor features an extracellular cysteine-rich domain (CRD1-4), a transmembrane region, and an intracellular death domain (DD). X-ray crystallography studies reveal that TNFRSF10B forms a trimeric complex upon binding to its ligand TRAIL, with each CRD domain maintaining its spatial conformation through a specific disulfide bond network, where CRD2 and CRD3 are key regions for ligand recognition. In terms of gene expression regulation, the TNFRSF10B gene is located on human chromosome 8p21.3, and its promoter contains multiple transcription factor binding sites, such as p53, NF-κB, and E2F1, which are activated during DNA damage, inflammatory stimulation, or cell cycle abnormalities, significantly upregulating TNFRSF10B expression. Epigenetic studies have shown that the methylation status of the TNFRSF10B promoter correlates with chemotherapy sensitivity in various cancers, and demethylating agents like 5-azacytidine can restore its expression. Notably, TNFRSF10B has multiple splice variants, including some lacking the death domain (e.g., DcR2), which act as decoy receptors to balance signaling pathways. In normal tissues, TNFRSF10B is highly expressed in the spleen, thymus, and activated lymphocytes, while its expression is often aberrant in tumor tissues due to epigenetic silencing or gene deletion.

Mechanisms of Death Receptor Signaling Pathway Activation

As a classic death receptor, TNFRSF10B signaling activation follows a highly ordered molecular cascade. When trimeric TRAIL ligand binds to TNFRSF10B, the receptor's death domain undergoes conformational changes, recruiting the adaptor protein FADD (Fas-associated death domain) through homotypic interactions. FADD further recruits procaspase-8/10 via its death effector domain (DED), forming the death-inducing signaling complex (DISC). Within the DISC, procaspase-8 undergoes autocleavage and activation, initiating two apoptotic pathways: in type I cells, caspase-8 directly activates effector caspases-3/6/7, executing rapid apoptosis; in type II cells, mitochondrial amplification is required, where Bid is cleaved into tBid, inducing mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release. Recent studies have identified multiple factors regulating TNFRSF10B signaling intensity: c-FLIP (cellular FLICE-inhibitory protein) competitively binds to the DISC, inhibiting caspase-8 activation; Bcl-2 family proteins modulate mitochondrial pathway sensitivity; and proteins like PED/PEA-15 affect DISC formation efficiency by sequestering FADD. Notably, TNFRSF10B can also activate non-apoptotic signaling pathways, such as NF-κB and MAPK pathways via RIPK1 and TRAF2, which under specific conditions promote cell survival and inflammatory responses.

Dual Roles in Tumor Development

TNFRSF10B exhibits a complex and paradoxical dual role in tumor biology, acting both as a tumor suppressor to induce apoptosis and, in specific microenvironments, promoting tumor progression. Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the TNFRSF10B locus associated with various cancer risks, particularly the rs1133782 polymorphism, which shows significant correlations with colorectal and breast cancer susceptibility. In liver and gastric cancers, hypermethylation of the TNFRSF10B promoter leads to its silencing, a key mechanism for tumor cells to evade apoptosis. Functional studies demonstrate that restoring TNFRSF10B expression significantly enhances tumor cell sensitivity to TRAIL and chemotherapy drugs, reducing tumor volume by 40-60% in xenograft models. However, paradoxically, in certain advanced tumors, TNFRSF10B promotes invasion and metastasis through non-apoptotic signaling: in prostate cancer, TNFRSF10B-activated NF-κB increases MMP-9 and VEGF expression; in gliomas, TNFRSF10B-mediated inflammatory responses promote M2 polarization of tumor-associated macrophages. This dual effect may be closely linked to microenvironmental oxygen levels, cell types, and genetic backgrounds. Clinical pathological analyses indicate that TNFRSF10B expression patterns have prognostic value: high expression in early-stage tumors predicts better treatment responses, while in metastatic tumors, it may correlate with poor outcomes.

Functions in Immune Regulation and Inflammatory Responses

Beyond its traditional role in apoptosis induction, TNFRSF10B is increasingly recognized for its pleiotropic functions in immune system regulation and inflammatory responses. In T cell immunity, TNFRSF10B modulates the function of TRAIL-expressing effector cells through "reverse signaling": in CD8+ cytotoxic T cells, TNFRSF10B signaling enhances IFN-γ production and killing activity, while in regulatory T cells (Tregs), it promotes the maintenance of suppressive functions. NK cell studies show that the TNFRSF10B-TRAIL axis is a critical effector mechanism in viral infection and tumor immune surveillance, with IL-15 and IFN-α significantly upregulating this pathway. Inflammatory disease models reveal that TNFRSF10B regulates the timing of neutrophil apoptosis, and its deficiency delays inflammation resolution and exacerbates tissue damage. In rheumatoid arthritis, synovial fibroblast overexpression of TNFRSF10B promotes inflammatory cytokine release and joint destruction via non-apoptotic signaling, while in inflammatory bowel disease, epithelial TNFRSF10B deficiency impairs intestinal barrier function and causes microbiota dysbiosis. Autoimmune disease research has identified TNFRSF10B gene polymorphisms associated with susceptibility to systemic lupus erythematosus (SLE) and Sjögren's syndrome, possibly by modulating B cell tolerance. Notably, in viral infections like HIV and HCV, TNFRSF10B-mediated apoptosis is a key mechanism for immune cell depletion, while some viruses have evolved DcR2-mimicking proteins to antagonize this pathway.

Targeted Therapeutic Strategies and Clinical Translation Progress

TNFRSF10B-based targeted therapies have become a research hotspot in oncology and autoimmune diseases, with several innovative treatments entering clinical evaluation. Agonistic antibodies like tigatuzumab (CS-1008) and conatumumab (AMG 655) mimic TRAIL to activate TNFRSF10B-mediated apoptosis, demonstrating favorable safety and preliminary efficacy in phase II trials for breast and colorectal cancers. To improve selectivity, next-generation bispecific antibodies like TRAIL-R2xCD3 simultaneously target TNFRSF10B and T cell receptors, inducing specific immune responses in solid tumor models. Small-molecule agonists like bioymifi and TIC10 overcome receptor silencing through allosteric activation or upregulation of TNFRSF10B expression, resensitizing resistant tumors in preclinical studies. In combination therapies, TNFRSF10B agonists paired with chemotherapy (e.g., oxaliplatin), targeted therapy (e.g., PARP inhibitors), or immune checkpoint inhibitors (e.g., PD-1 antibodies) show synergistic effects, with multiple phase III trials underway. Gene therapy strategies, such as TRAIL gene-modified mesenchymal stem cells, enable localized high-concentration delivery in tumors, significantly prolonging survival in glioblastoma models. However, clinical translation faces challenges: hypoxic and acidic tumor microenvironments inhibit DISC formation; some tumors overexpress decoy receptors DcR1/2; systemic administration may cause hepatotoxicity. To address these issues, novel pH-sensitive nanocarriers and conditionally replicating adenoviruses are under development to enhance targeting and safety.

Future Research Directions and Translational Medicine Prospects

The TNFRSF10B research field is advancing toward greater precision and depth, with several innovative directions driving clinical translation. Single-cell multi-omics technologies will unveil cell-type-specific regulatory networks of TNFRSF10B, such as unique epigenetic silencing mechanisms in cancer stem cells. Structure-guided rational design will yield next-generation allosteric agonists that selectively activate apoptotic over pro-survival pathways, such as small-molecule compounds targeting specific CRD2 pockets. In nanotechnology, exosome-delivered TNFRSF10B siRNA can modulate immune cell activity in inflammatory sites, while gold nanorod-conjugated TRAIL enables photothermal-apoptosis combination therapy. Immunometabolism research has revealed that TNFRSF10B signaling is closely linked to mitochondrial metabolic reprogramming, offering new avenues for targeting energy metabolism. In diagnostics, liquid biopsy technologies based on TNFRSF10B epigenetic markers, such as detecting TNFRSF10B promoter methylation in circulating DNA, can predict treatment responses early. Gene editing tools like CRISPR-Cas9 can create TNFRSF10B reporter models for high-throughput drug screening and resistance mechanism studies. Clinical applications will expand into emerging areas: integrating TNFRSF10B signaling in CAR-T cells to enhance persistence; regulating myofibroblast apoptosis in fibrotic diseases; and controlling neuroinflammation in neurodegenerative disorders. Over the next five years, 3-5 novel TNFRSF10B-targeted drugs are expected to gain approval, and with AI-predicted biomarkers, truly personalized precision medicine will become a reality.

Click on the product catalog numbers below to access detailed information on our official website.

Product Information

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.